Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
2(22%)
Results Posted
67%(2 trials)
Terminated
3(33%)

Phase Distribution

Ph early_phase_1
1
11%
Ph not_applicable
1
11%
Ph phase_1
6
67%
Ph phase_2
1
11%

Phase Distribution

7

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(3)
Terminated(3)
Other(1)

Detailed Status

Terminated3
Completed3
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 16 (66.7%)
Phase 21 (11.1%)
N/A1 (11.1%)

Trials by Status

recruiting222%
unknown111%
terminated333%
completed333%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_1

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

NCT05210374
recruitingnot_applicable

Copper Supplementation in Cirrhosis

NCT07471542
completedphase_1

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT02715609
terminatedphase_2

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

NCT03363659
terminatedphase_1

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

NCT04521335
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05210374Phase 1

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Recruiting
NCT07471542Not Applicable

Copper Supplementation in Cirrhosis

Recruiting
NCT02715609Phase 1

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed
NCT03363659Phase 2

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Terminated
NCT04521335Phase 1

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Terminated
NCT02963051Phase 1

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Terminated
NCT01907165Early Phase 1

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

Completed
NCT01177579Phase 1

Human Biomarkers for Assessing Copper Deficiency

Unknown
NCT00742911Phase 1

Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver

Completed

All 9 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
9